全文获取类型
| 收费全文 | 2489651篇 |
| 免费 | 175354篇 |
| 国内免费 | 10760篇 |
专业分类
| 耳鼻咽喉 | 34202篇 |
| 儿科学 | 76576篇 |
| 妇产科学 | 69274篇 |
| 基础医学 | 341655篇 |
| 口腔科学 | 71066篇 |
| 临床医学 | 219027篇 |
| 内科学 | 493359篇 |
| 皮肤病学 | 57398篇 |
| 神经病学 | 200219篇 |
| 特种医学 | 99945篇 |
| 外国民族医学 | 651篇 |
| 外科学 | 384406篇 |
| 综合类 | 63174篇 |
| 现状与发展 | 20篇 |
| 一般理论 | 814篇 |
| 预防医学 | 185109篇 |
| 眼科学 | 56032篇 |
| 药学 | 181570篇 |
| 71篇 | |
| 中国医学 | 6671篇 |
| 肿瘤学 | 134526篇 |
出版年
| 2018年 | 24207篇 |
| 2016年 | 22374篇 |
| 2015年 | 25488篇 |
| 2014年 | 35261篇 |
| 2013年 | 52048篇 |
| 2012年 | 66168篇 |
| 2011年 | 70634篇 |
| 2010年 | 43270篇 |
| 2009年 | 41808篇 |
| 2008年 | 66160篇 |
| 2007年 | 71328篇 |
| 2006年 | 72561篇 |
| 2005年 | 70335篇 |
| 2004年 | 67224篇 |
| 2003年 | 65423篇 |
| 2002年 | 62951篇 |
| 2001年 | 115999篇 |
| 2000年 | 119754篇 |
| 1999年 | 100946篇 |
| 1998年 | 29240篇 |
| 1997年 | 26481篇 |
| 1996年 | 26660篇 |
| 1995年 | 26164篇 |
| 1994年 | 24378篇 |
| 1993年 | 22713篇 |
| 1992年 | 80906篇 |
| 1991年 | 78563篇 |
| 1990年 | 76226篇 |
| 1989年 | 73597篇 |
| 1988年 | 68368篇 |
| 1987年 | 67348篇 |
| 1986年 | 63923篇 |
| 1985年 | 61143篇 |
| 1984年 | 46378篇 |
| 1983年 | 39120篇 |
| 1982年 | 23994篇 |
| 1981年 | 21787篇 |
| 1980年 | 20423篇 |
| 1979年 | 43002篇 |
| 1978年 | 31013篇 |
| 1977年 | 26580篇 |
| 1976年 | 24197篇 |
| 1975年 | 26331篇 |
| 1974年 | 31214篇 |
| 1973年 | 30101篇 |
| 1972年 | 28372篇 |
| 1971年 | 26467篇 |
| 1970年 | 24640篇 |
| 1969年 | 23443篇 |
| 1968年 | 21940篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
61.
V. Jenkins I. Solis-Trapala H. Payne M. Mason L. Fallowfield S. May L. Matthews S. Catt 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(2):99-107
Aims
Delaying progression, ameliorating symptoms and maintaining quality of life (QoL) are primary aims of treatment for metastatic castrate-resistant prostate cancer (mCRPC). Real-world rather than clinical trial data about symptoms and side-effects are sparse. In EXTREQOL, patients' QoL, pain and information needs were recorded during treatment.Material and methods
Men with mCRPC from 20 UK cancer centres starting various systemic mCRPC treatments completed QoL, pain and information needs questionnaires at baseline, 3 and 6 months.Results
In total, 132 patients were recruited. Overall QoL declined significantly by 6 months (Functional Assessment of Cancer Therapy-Prostate [FACT-P] mean = –3.89, 95% confidence interval –6.7 to –1.05, P = 0.007; Trial Outcome Index [TOI] analysis mean = –3.10, 95% confidence interval –5.34 to –0.83, P = 0.007). Those who came off novel therapy and remained on luteinising hormone-releasing hormone agonist therapy alone had worse scores than patients receiving concomitant chemotherapy (Prostate Concerns Subscale mean difference = –4.45, 95% confidence interval –7.06 to –1.83, P = 0.001; TOI mean difference = –5.62, 95% confidence interval –10.97 to –0.26, P = 0.040). At 3 and 6 months, men who reported pain at baseline improved (43%, 40%), but for others pain levels remained the same (45%, 42%) or worsened (13%, 18%). Information regarding supportive care was lacking throughout the period of time on the study.Conclusion
Most mCRPC treated patients experience reduced QoL and inadequate pain control. More help with pain management and better information provision regarding supportive care is warranted. 相似文献62.
K.A. Lee M.T.A. Sharabiani D. Tumino J. Wadsley V. Gill G. Gerrard R. Sindhu M.N. Gaze L. Moss K. Newbold 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(6):385-390
Aims
To obtain an overview of the management and outcomes of children aged 18 years or younger diagnosed with differentiated thyroid carcinoma of follicular cell origin across the UK, by collecting and analysing data from the limited number of centres treating these patients. This multicentre data might provide a more realistic perspective than single-institution series.Materials and methods
Six centres submitted data extracted from historical records on patients aged 18 years or younger, diagnosed between 1964 and 2017. The univariate and multivariable Cox proportional hazard model was used to identify potential predictors of progression-free survival, using national data as a control.Results
Data on 166 patients were available for analysis. Females (74%) were predominant, and the age ranged from 3 to 19 years at diagnosis, mean 14.1 years. Nodal metastases were present in 51%; 12% had distant metastases. After surgery, 95% received radioactive iodine (39% on more than one occasion) and 4% received external beam radiotherapy. With a median follow-up duration of 5 years, 69% are alive with no evidence of disease; 20% are alive with a raised thyroglobulin level as the only evidence of residual disease; 6% have residual structural disease detectable on imaging; 2% have died, from cerebral metastases.Conclusion
Despite most patients having advanced disease at presentation, outcomes are very good. A national prospective registry should allow systematic collection of good-quality data and may facilitate research to further improve outcomes. 相似文献63.
Edward J.A. Harris Steven Kao Brian McCaughan Takashi Nakano Nobuyuki Kondo Rebecca Hyland Anna K. Nowak Nicholas H. de Klerk Fraser J.H. Brims 《Journal of thoracic oncology》2019,14(2):288-293
Introduction
Malignant pleural mesothelioma (MPM) is an uncommon cancer with a poor prognosis and heterogeneous survival. Surgery for MPM is offered in some specialist centers to highly selected patients. A previously described classification and regression tree (CART) model stratified survival in unselected MPM patients using routinely collected clinical data. This study aimed to examine the performance of this CART model on a highly selected surgical population.Methods
Data were collected from subjects undergoing cytoreductive surgery for MPM from specialist centers in Hyõgo, Japan, and Sydney, Australia, between 1991 and 2016. The CART model was applied using the combination of clinical variables to stratify subjects into risk groups (1 through 4); survival characteristics were then compared.Results
Two hundred eighty-nine cases were included (205 from Australia, 84 from Japan). Overall median survival was 34.6 (interquartile range: 17.5–56.1) months; median age was 63.0 (interquartile range: 57.0–67.8) years, and 83.0% (n = 240) were male. There were no clinically meaningful differences between the two cohorts. Survival across the four risk groups was significantly different (p < 0.0001); the model stratified survival well with a Harrell's concordance statistic of 0.62 (95% confidence interval: 0.57–0.66) at 36 months. The group with the longest survival (median, 82.5 months) had: no weight loss, hemoglobin > 153 g/L and serum albumin > 43 g/L at time of referral to the surgical center.Conclusions
Using routinely available clinical variables, the CART model was able to stratify surgical patients into risk groups with statistically different survival characteristics with fair to good performance. Presence of weight loss, anemia, and low albumin should confer caution when considering surgical therapy for MPM. 相似文献64.
Shuning Ding Jiayi Wu Caijin Lin Weiguo Chen Yafen Li Kunwei Shen Li Zhu 《Clinical breast cancer》2019,19(1):e66-e73
Background
Pure mucinous breast cancer (PMBC) is a rare pathologic type of breast cancer, the prognostic factors of which have not been clearly defined. This study aimed to analyze the prognostic markers and distribution of 21-gene recurrence score (RS) in patients with PMBC.Patients and Methods
Utilizing the Surveillance, Epidemiology, and End Results (SEER) database, a retrospective analysis of PMBC cases was conducted. Multivariate analyses were used to evaluate the indicators for prognosis and the correlations between RS and traditional clinicopathologic characteristics. Disease was subdivided into 4 molecular phenotypes using estrogen receptor (ER) status and tumor grade.Results
Of the 8048 patients, most had ER-positive and node-negative tumors. Multivariate analysis revealed that molecular phenotype as well as age, race, tumor size, and lymph node status was an independent prognostic factor for patients with PMBC (P < .05). The 5-year breast cancer–specific survival of patients among different phenotypes was significantly different (97.9% for ER-positive and grade I tumor, 96.9% for ER-positive and grade II-III tumor, 96% for ER-negative and grade I tumor, 90.1% for ER-negative and grade II-III tumors, P < .001). The proportions of patients categorized into low, intermediate, and high RS risk group were 64.9%, 31.9%, and 3.2%, respectively. Grade, progesterone receptor status, and age were identified as independent variables associated with RS.Conclusion
PMBC had favorable biological features and relatively good prognosis. Molecular phenotype as well as age, race, tumor size, and lymph node status were independent prognostic markers. Furthermore, age, progesterone receptor status, and grade could independently predict RS. 相似文献65.
Georg Hahn Sharon M. Lutz Julian Hecker Dmitry Prokopenko Michael H. Cho Edwin K. Silverman Scott T. Weiss Christoph Lange 《Genetic epidemiology》2021,45(1):82-98
locStra is an ‐package for the analysis of regional and global population stratification in whole‐genome sequencing (WGS) studies, where regional stratification refers to the substructure defined by the loci in a particular region on the genome. Population substructure can be assessed based on the genetic covariance matrix, the genomic relationship matrix, and the unweighted/weighted genetic Jaccard similarity matrix. Using a sliding window approach, the regional similarity matrices are compared with the global ones, based on user‐defined window sizes and metrics, for example, the correlation between regional and global eigenvectors. An algorithm for the specification of the window size is provided. As the implementation fully exploits sparse matrix algebra and is written in C++, the analysis is highly efficient. Even on single cores, for realistic study sizes (several thousand subjects, several million rare variants per subject), the runtime for the genome‐wide computation of all regional similarity matrices does typically not exceed one hour, enabling an unprecedented investigation of regional stratification across the entire genome. The package is applied to three WGS studies, illustrating the varying patterns of regional substructure across the genome and its beneficial effects on association testing. 相似文献
66.
Mélanie Hébert Raymond Cartier François Dagenais Yves Langlois Marianne Coutu Nicolas Noiseux Ismail El-Hamamsy Louis-Mathieu Stevens 《Seminars in thoracic and cardiovascular surgery》2021,33(2):443-451
- Download : Download high-res image (184KB)
- Download : Download full-size image
67.
68.
Gregory Lazarian Shanye Yin Elisa ten Hacken Tomasz Sewastianik Mohamed Uduman Alba Font-Tello Satyen H. Gohil Shuqiang Li Ekaterina Kim Heather Joyal Leah Billington Elizabeth Witten Mei Zheng Teddy Huang Mariano Severgnini Valerie Lefebvre Laura Z. Rassenti Catherine Gutierrez Catherine J. Wu 《Cancer cell》2021,39(3):380-393.e8
- Download : Download high-res image (201KB)
- Download : Download full-size image
69.
Dae Won Kim Elaine Tan Jun-Min Zhou Michael J. Schell Maria Martinez James Yu Estrella Carballido Rutika Mehta Jonathan Strosberg Iman Imanirad Richard D. Kim 《British journal of cancer》2021,124(11):1803
Background MMR proficient (pMMR) colorectal cancer (CRC) is usually unresponsive to immunotherapy. Recent data suggest that ibrutinib may enhance the anti-tumour activity of anti-PD-1 immunotherapy. In this study, we evaluated the safety and efficacy of ibrutinib plus pembrolizumab in refractory metastatic CRC.Methods This was a phase 1/2 study in patients with refractory metastatic pMMR CRC. The primary endpoints for phases 1 and 2 were maximum tolerated dose (MTD) and disease control rate, respectively. The secondary endpoints were safety, progression-free survival (PFS) and overall survival (OS).Results A total of 40 patients were enrolled. No dose-limiting toxicity was observed, and MTD was not identified. The highest tested dose of ibrutinib, 560 mg once daily, was combined with a fixed dose of pembrolizumab 200 mg every 3 weeks for the phase 2 portion. The most common grade 3/4 treatment-related adverse events were anaemia (21%), fatigue (8%) and elevated alkaline phosphatase (8%). Among 31 evaluable patients, 8 (26%) achieved stable disease, and no objective response was observed. The median PFS and OS were 1.4 and 6.6 months, respectively.Conclusion Ibrutinib 560 mg daily plus pembrolizumab 200 mg every 3 weeks appears to be well tolerated with limited anti-cancer activity in metastatic CRC.ClinicalTrials.gov identifier NCT03332498.Subject terms: Cancer immunotherapy, Colorectal cancer 相似文献
70.
Sarah J. Schrauben Haochang Shou Xiaoming Zhang Amanda Hyre Anderson Joseph V. Bonventre Jing Chen Steven Coca Susan L. Furth Jason H. Greenberg Orlando M. Gutierrez Joachim H. Ix James P. Lash Chirag R. Parikh Casey M. Rebholz Venkata Sabbisetti Mark J. Sarnak Michael G. Shlipak Sushrut S. Waikar Paul L. Kimmel Ramachandran S. Vasan Harold I. Feldman Jeffrey R. Schelling 《Journal of the American Society of Nephrology : JASN》2021,32(1):115